FOLH1 and posterior cortical atrophy: To provide a clear comparison of the principal treatment modalities for advanced PCa—including AR pathway inhibitors, PARP inhibitors, immuno-oncology strategies, and PSMA-targeted approaches—we summarize their key mechanisms, benefits, limitations, and associated biomarkers in Table 7.